Business Wire

TX-EMIST

2.11.2020 14:02:05 CET | Business Wire | Press release

Share
Small Size. Big Performance.

EMist® Disinfection Solutions today announced the launch of the EX-7000 Tru Electrostatic™ Disinfectant Sprayer.

The EX-7000 is lightweight and ergonomic weighing in at just 14.9 pounds making it one-half lighter than other sprayers. Equipped with intelligent Charge Detect™ Technology, the EX-7000 electrostatic sprayer continuously detects the polarity of the user and the equipment and adjusts automatically so that grounding is never an issue, ensuring the most comprehensive disinfectant coating in the industry, and reducing labor and chemical costs by 50 percent.

Disinfectant is first atomized, passes through an electrostatic-induction nozzle, charged using a bipolar power supply, and then discharged toward the target area. The bipolar supply causes the electrical charges to be alternatively redistributed, resulting in droplets having an excess of either positive or negative charges. These charged droplets are so attracted to the targeted area that they coat the sides, edges, and backside of surfaces.

EMist’s TruElectrostatic Disinfectant Sprayers are built on six core platforms, resulting in an electrostatic sprayer that provides 100 percent continuous electrostatic charge output, eliminates grounding, yielding superior, comprehensive coverage.

TruTechnology: EPIX Charge Detect Technology

Using EPIX Charge Detect Technology, the electrostatic sprayers continuously detect the polarity of the user and the equipment and adjusts automatically so that grounding is never an issue. The discharged droplets wrap around surfaces. This wraparound effect creates an even, consistent and comprehensive coverage of chemical, reducing chemical and labor costs.

TruConfidence: Patented. Proven. Trusted.

Since the emergence of COVID-19, many companies have appeared overnight claiming they have electrostatic sprayers. When dealing with life-threatening pathogens, it’s critically important to know that the company you’re buying from is experienced, respected, and proven. EMist electrostatic sprayers are patented, backed by independent lab studies, used during the 2014 Ebola crisis, and developed by electrostatic industry veteran Mike Sides, who frequently works with the Department of Defense, Naval Entomology Center of Excellence, USDA, and the World Health Organization.

TruCharge: Best Performance

Electrostatic sprayer polarity matters. Most surfaces have a negative or neutral charge (the earth itself is negative). Per the EPA, electrostatic sprayers should impart a positive charge so that the positively charged disinfectant droplets are attracted to targeted negative or neutral surfaces. Positively charged droplets increase droplet adhesion and wrap.

TruDesign: Safer Operation

When spraying big areas, big buildings, or tight spaces, a cordless sprayer allows you to maneuver and move about freely. EMist sprayers are ergonomic, lightweight, and cordless. That means operators can take the sprayer to where the work needs to be done rather than relying on wall outlets at the work site. Portability is a clear advantage for any user who needs to go where the work is to get the job done right.

TruAssurance: User Safety

Per the EPA, electrostatic disinfectant sprayers should have a median droplet size greater than 40 microns. Droplets must be large enough to resist evaporation and drift but small enough that the droplets can change their trajectory when it comes close to a target. Most competitor sprayers produce droplets of less than 40 microns making them highly drift-prone and increasing user inhalation concerns. EMist sprayers maintain a median droplet size of 75 microns.

TruCost: Lower Total Cost of Ownership

Based on the need to disinfect large areas, manual application of disinfectants is a thing of the past. Electrostatic application is the new normal. Customers using EMist systems typically see up to 50 percent reduction in labor and chemical costs. Competitively priced, advanced and patented electrostatic technology, and proven performance provide an overall lower total cost of ownership.

EMist has announced a reservation program for purchasers who want to secure their units in December. The company will begin taking refundable $50 reservations on its official website starting on November 2 at 8 a.m. Central Time. The EX-7000 is available through EMist distributors at a list price of $3,995 USD.

About EMist

Headquartered in Fort Worth, Texas, EMist develops intelligent electrostatic disinfectant sprayers that make spaces healthier. For more information, visit EMist.com .

Social Media:

https://www.facebook.com/emistsolutions

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye